newsfilter
← Latest News
GlobeNewswire·

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCY-247's IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal